A REVIEW ON THE ANTIPARASITIC DRUG IVERMECTIN FOR VARIOUS VIRAL INFECTIONS AND POSSIBILITIES OF USING IT FOR NOVEL SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2: NEW HOPE TO TREAT CORONAVIRUS DISEASE-2019
| Autor: | Mohd Abdul Khader, Shayestha Jabeen, Talha Jabeen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
Antiparasitic medicine.drug_class viruses media_common.quotation_subject Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Pharmaceutical Science 02 engineering and technology medicine.disease_cause Bioinformatics 03 medical and health sciences 0302 clinical medicine Ivermectin Pharmacokinetics Medicine Pharmacology (medical) 030212 general & internal medicine media_common Coronavirus Pharmacology business.industry Immunogenicity 021001 nanoscience & nanotechnology Drug repositioning 0210 nano-technology business medicine.drug |
| Zdroj: | Asian Journal of Pharmaceutical and Clinical Research. :21-27 |
| ISSN: | 2455-3891 0974-2441 |
| DOI: | 10.22159/ajpcr.2020.v13i8.38357 |
| Popis: | The novel coronavirus infection has spread all over the world. With no specific drug or vaccine, the process of “drug repurposing” becomes a feasible solution. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has 80% sequence similarity with the SARS-CoV, the nuclear import inhibitor “Ivermectin” (IVM) has recently been studied as a possible treatment option for coronavirus disease-2019 (COVID-19). The article aims to provide a review on structure and immunogenicity of SARS-CoV-2, indications of IVM for viral diseases, its possible mechanism on COVID-19 with a brief discussion on IVM structure, pharmacokinetics, adverse drug reactions, drug interactions, and contraindications. Further, we made possible comparisons of IVM with solidarity trial drugs and analyzed its major advantages, limitations and gave necessary recommendations for its use in future in vivo studies in the treatment of COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|